Average Co-Inventor Count = 5.49
ph-index = 8
The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.
Company Filing History:
1. Bioverativ Therapeutics Inc. (7 from 73 patents)
2. Aventis Pharmaceuticals Inc. (5 from 207 patents)
3. Dyax Corporation (3 from 173 patents)
4. Syntonix Pharmaceuticals, Inc. (2 from 14 patents)
5. Biogen Hemophilia Inc. (2 from 2 patents)
6. Other (1 from 832,880 patents)
7. Biogen Idec Hemophilia Inc. (1 from 5 patents)
8. Swedish Orphan Biovitrum Ab (1 from 2 patents)
18 patents:
1. 12257288 - Methods of inducing immune tolerance to clotting factors
2. 12186375 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
3. 12161696 - Methods of treating hemophilic arthropathy using chimeric clotting factors
4. 11266720 - Factor VIII-FC chimeric and hybrid polypeptides, and methods of use thereof
5. 10881742 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
6. 10023628 - Cell line expressing single chain factor VIII polypeptides and uses thereof
7. 10010622 - Factor VIII chimeric and hybrid polypeptides, and methods of use thereof
8. 9260520 - Antibodies to FeRn and uses thereof
9. 9241978 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
10. 9050318 - Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
11. 8815246 - Fc receptor binding proteins
12. 8273351 - Fc receptor binding proteins
13. 7429595 - Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
14. 6861524 - Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
15. 6642231 - 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines